Biomarin Pharmaceutical Inc Revenue Growth Rates (BMRN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biomarin Pharmaceutical Inc  (NASDAQ: BMRN)
 

BMRN's Revenue Growth by Quarter and Year

Biomarin Pharmaceutical Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BMRN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 989.71
1st Quarter March 766.21
FY 1,755.92

BMRNs Annual Revenue
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2025 $ 3,221.25 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2024 $ 2,853.92 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2023 $ 2,419.23 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2022 $ 2,096.04 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2021 $ 1,846.28 millions




BMRN Revenue second quarter 2026 Y/Y Growth Comment
Biomarin Pharmaceutical Inc achieved in the second quarter 2026, above Company average Revenue increase of 19.91% year on year, to $ 989.71 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue growth. While Biomarin Pharmaceutical Inc' s Revenue growth of 19.91% ranks overall at the positon no. 1041 in the second quarter 2026.


BMRN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 17.03 % 15.65 % 20.22 %
3rd Quarter September - 4.08 % 28.28 % 15.04 %
2nd Quarter June 19.91 % 15.92 % 19.61 % 11.52 %
1st Quarter March 2.83 % 14.85 % 8.79 % 14.84 %
FY   - 12.87 % 17.97 % -

Financial Statements
Biomarin Pharmaceutical Inc's second quarter 2026 Revenue $ 989.71 millions BMRN's Income Statement
Biomarin Pharmaceutical Inc's second quarter 2025 Revenue $ 825.41 millions Quarterly BMRN's Income Statement


BMRN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 12.68 % 0.21 % 11.16 %
3rd Quarter September - -5.97 % 4.73 % -2.34 %
2nd Quarter June 29.17 % 10.77 % 9.74 % -0.19 %
1st Quarter March -12.39 % -0.29 % 0.41 % 10.95 %
FY (Year on Year)   - 12.87 % 17.97 % -


Back to BMRN Growth rate Comparisons >> Back to BMRN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #208
Overall #1041

Revenue Y/Y Growth Statistics
High Average Low
57.18 % 15.03 % -36.91 %
(Mar 31 2015)   (Mar 31 2011)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #208
Overall #1041
Revenue Y/Y Growth Statistics
High Average Low
57.18 % 15.03 % -36.91 %
(Mar 31 2015)   (Mar 31 2011)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biomarin Pharmaceutical Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
99.32 % 4.87 % -47.25 %
(Dec 31 2009)  


BMRN's II. Quarter Q/Q Revenue Comment
Biomarin Pharmaceutical Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 29.17%, to $ 989.71 millions, from $766.21 millions in the first quarter.
BMRN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Biomarin Pharmaceutical Inc's Revenue growth quarter on quarter, overall rank is 377.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #377
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #377
Revenue Q/Q Growth Statistics
High Average Low
99.32 % 4.87 % -47.25 %
(Dec 31 2009)  


BMRN's II. Quarter Q/Q Revenue Comment
Biomarin Pharmaceutical Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 29.17%, to $ 989.71 millions, from $766.21 millions in the first quarter.
BMRN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Biomarin Pharmaceutical Inc's Revenue growth quarter on quarter, overall rank is 377.


Biomarin Pharmaceutical Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3,406.61 $ 3,242.32 $ 3,221.25 $ 3,094.00 $ 3,063.61
Y / Y Revenue Growth (TTM) 11.2 % 9.9 % 12.87 % 12.39 % 18.36 %
Year on Year Revenue Growth Overall Ranking # 922 # 784 # 443 # 238 # 721
Seqeuential Revenue Change (TTM) 5.07 % 0.65 % 4.11 % 0.99 % 3.84 %
Seq. Revenue Growth (TTM) Overall Ranking # 2196 # 1432 # 1332 # 1159 # 1543


Cumulative Revenue growth Comment
Although Biomarin Pharmaceutical Inc's Annual Revenue growth year on year were below company's average 14.62% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.2% year on year, from 9.9% in Mar 31 2026.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 784 to 922.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 182
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
40.31 %
 14.62 %
-2.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 2196
Cumulative Revenue growth Comment
Although Biomarin Pharmaceutical Inc's Annual Revenue growth year on year were below company's average 14.62% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.2% year on year, from 9.9% in Mar 31 2026.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 784 to 922.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 182
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
40.31 %
14.62 %
-2.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 2196




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMRN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions


About Biomarin Pharmaceutical Inc Revenue Growth Rates (BMRN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biomarin Pharmaceutical Inc (CIK 1048477).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001048477-26-000016
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biomarin Pharmaceutical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.